NCRP addresses consequences of radiation therapy

A new report from the National Council on Radiation Protection and Measurements (NCRP) presents several conclusions and recommendations regarding the risks of radiotherapy in cancer treatment.

Second malignant neoplasms (SMNs) and cardiovascular disease (CVD) are among the most serious and life-threatening late adverse effects experienced by the growing number of cancer survivors worldwide and are due in part to radiotherapy, explained the report authors in a detailed summary published in Journal of the National Cancer Institute (2012;104[5]:357-370). The goal of the NCRP is to develop solid long-term risk estimates and prediction models, establish research priorities, and identify concrete ways to prevent serious additional health problems in cancer survivors.

Some key findings of the NCRP are as follows:

  • Although newer radiotherapy methods result in a different distribution of the radiation to organs and tissue than do older regimens, current models used to assess risk of SMNs and CVD are often based on the older treatments. Newer risk-prediction models should be based on the dose absorbed by the organ and the type of radiation prescribed.
  • Modern radiation techniques and lower doses result in a much smaller risk of heart problems for patients, but an important noncancer cause of death for some survivors is radiation-related CVD, including pericardial disease, coronary artery disease, valvular dysfunction, conduction abnormalities, and stroke.
  • Few studies have described survival after the diagnosis of an SMN.
  • More studies are needed to analyze all aspects of the relationship between radiation dose and risks of SMNs and CVD.
  • Follow-up studies of cancer survivors should evaluate populations treated with such modern radiotherapy methods as tomotherapy and cyber knife, and at reduced field sizes and lower dosages.
  • Interactions between radiotherapy and other potential confounding factors, such as age, sex, race, tobacco and alcohol use, dietary intake, energy balance, and genetic susceptibility should be investigated.

The NCRP also calls for the construction of comprehensive risk-prediction models for SMNs and CVD so that follow-up guidelines and prevention and intervention strategies can be developed.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs